Literature DB >> 8872613

Retinoblastoma protein family in cell cycle and cancer: a review.

M G Paggi1, A Baldi, F Bonetto, A Giordano.   

Abstract

Two genes, p107 and Rb2/p130, are strictly related to RB, the most investigated tumor suppressor gene, responsible for susceptibility to retinoblastoma. The products of these three genes, namely pRb, p107, and pRb2/p130 are characterized by a peculiar steric conformation, called "pocket," responsible for most of the functional interactions characterizing the activity of these proteins in the homeostasis of the cell cycle. The interest in these genes and proteins springs from their ability to regulate cell cycle processes negatively, being able, for example, to dramatically slow down neoplastic growth. So far, among these genes, only RB is firmly established to act as a tumor suppressor, because its lack-of-function is clearly involved in tumor onset and progression. It has been found deleted or mutated in most retinoblastomas and sarcomas, but its inactivation is likely to play a crucial role in other types of human cancers. The two other members of the family have been discovered more recently and are currently under extensive investigation. We review analogies and differences among the pocket protein family members, in an attempt to understand their functions in normal and cancer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872613     DOI: 10.1002/(SICI)1097-4644(199609)62:3%3C418::AID-JCB12%3E3.0.CO;2-E

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  34 in total

1.  Interactions between human cytomegalovirus IE1-72 and cellular p107: functional domains and mechanisms of up-regulation of cyclin E/cdk2 kinase activity.

Authors:  Zhigang Zhang; Shu-Mei Huong; Xin Wang; David Y Huang; Eng-Shang Huang
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins.

Authors:  A V Samuelson; S W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Analysis of gene expression identifies candidate molecular markers in nasopharyngeal carcinoma using microdissection and cDNA microarray.

Authors:  Zhaoyang Zeng; Yanhong Zhou; Wei Xiong; Xiaomin Luo; Wenling Zhang; Xiaoling Li; Songqing Fan; Li Cao; Ke Tang; Minghua Wu; Guiyuan Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-21       Impact factor: 4.553

4.  Retinoblastoma protein regulation by the COP9 signalosome.

Authors:  Zakir Ullah; Martin S Buckley; David N Arnosti; R William Henry
Journal:  Mol Biol Cell       Date:  2007-01-24       Impact factor: 4.138

5.  Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2, and E47.

Authors:  Yi Qiu; Min Guo; Suming Huang; Roland Stein
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

6.  The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase.

Authors:  R Ferreira; L Magnaghi-Jaulin; P Robin; A Harel-Bellan; D Trouche
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

7.  Close linkage of p130 and Ft1 is conserved among mammals.

Authors:  R Lesche; U Rüther
Journal:  Mamm Genome       Date:  1998-03       Impact factor: 2.957

Review 8.  E2F transcription factor action, regulation and possible role in human cancer.

Authors:  T L Sladek
Journal:  Cell Prolif       Date:  1997 Mar-Apr       Impact factor: 6.831

Review 9.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

10.  Clinicopathological significance of pRb2/p130 expression in squamous cell carcinoma of the esophagus.

Authors:  T Nozoe; D Korenaga; S Itoh; M Futatsugi; Y Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2002-11-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.